Medicare locks in wound-care prices, FDA fast-tracks tissue products
H.R. 6852 — Advanced Wound Care and Regenerative Medicine Access and Reform Act · Filed by Gabe Evans (R-CO) · 2 cosponsors · Introduced Dec 18, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new Medicare payment system for skin substitute products (cellular or tissue-based wound treatments) starting January 2026, setting initial reimbursement based on 2023 pricing data and tying future increases to inflation. It also requires Medicare to identify high-billing providers of these products for fraud review, implement prior authorization for outlier providers, and directs the FDA to streamline approval processes for human tissue products while maintaining safety standards. The bill benefits wound-care manufacturers and regenerative medicine companies by establishing stable, predictable Medicare reimbursement; patients may benefit from faster FDA approval timelines, though the fraud-monitoring provisions suggest concern about overutilization.
Why we flagged it
The bill's core function is establishing a new Medicare reimbursement pathway for skin substitute products and streamlining FDA approval for tissue-based therapies. While framed as 'access and reform,' the primary mechanism is a payment-rate lock tied to 2023 baseline data, which directly benefits manufacturers by guaranteeing stable reimbursement.
What the text implies
- The 2023 volume-weighted average payment lock may insulate manufacturers from price competition indefinitely, as future increases are capped at inflation rather than market-driven adjustments.
- The 'reasonable and necessary portion' definition (greater of 3 sq cm or 120% of wound size) effectively guarantees reimbursement for up to 20% product wastage, shifting waste costs to Medicare rather than manufacturers.
The full analysis lists 5 implications of this text.
Who stands to gain
Skin substitute product manufacturers (e.g., Organogenesis, Mimedx, Apligraf producers); Regenerative medicine companies; Tissue banks and procurement organizations